此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Full-Thickness Macular Hole Surgery: A Comparison of Ten Techniques (FTMH-10)

2026年5月29日 更新者:Kairat Ruslanuly、Kazakh Eye Research Institute

Vitreoretinal Surgery for Full-Thickness Macular Hole: A Comparative Study of Ten Techniques

This study compares ten modern vitreoretinal surgical techniques for full-thickness macular hole repair. Participants will be randomly assigned to one of the surgical approaches during pars plana vitrectomy, using stratified randomization based on macular hole size to ensure balanced groups. The main goal is to determine which technique provides the highest anatomical closure rate on optical coherence tomography (OCT) and the best visual outcomes. Follow-up visits are scheduled at Day 7, Month 1, and Year 1 after surgery to assess OCT findings, visual acuity, safety outcomes, and the need for reoperation.

研究概览

详细说明

Full-thickness macular hole is a vision-threatening condition that is commonly treated with pars plana vitrectomy (PPV) and internal limiting membrane (ILM) peeling. While standard approaches achieve high closure rates in many cases, outcomes may vary depending on macular hole size and OCT morphology, and advanced surgical strategies (e.g., different ILM flap configurations, adjunctive biologic augmentation, hydrodissection, or grafting techniques) are increasingly used in clinical practice.

This single-center, randomized, parallel-group interventional study will compare ten PPV-based surgical techniques for full-thickness macular hole repair. Eligible participants will include adults with full-thickness macular hole across a broad range of minimum linear diameter (MLD), including MLD <250 µm. After eligibility confirmation and informed consent, participants will be randomized to one of the ten procedure groups. Randomization will be stratified by macular hole size into five predefined MLD strata to ensure balanced distribution of hole sizes across all intervention groups. Postoperative care and follow-up procedures will be standardized across groups according to the study protocol.

Follow-up visits are scheduled at Day 7, Month 1, and Year 1 after surgery and will include clinical examinations and OCT imaging. The primary endpoint is anatomical macular hole closure on OCT at the prespecified primary time point. Secondary endpoints include best-corrected visual acuity (BCVA), OCT-based morphologic recovery parameters, intraoperative and postoperative complication rates, reoperation rates, and adverse event information through Year 1. The study aims to generate evidence to guide selection of surgical technique based on macular hole morphometric and clinical characteristics while maintaining patient safety.

研究类型

介入性

注册 (估计的)

120

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Almaty
      • Almaty、Almaty、哈萨克斯坦、050042
        • 招聘中
        • Kazakh Eye Research Institute
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

Adults aged ≥18 years.

Full-thickness macular hole (FTMH) eligible for pars plana vitrectomy (PPV).

Symptom duration ≤12 months.

Clear ocular media sufficient for high-quality OCT imaging.

No prior pars plana vitrectomy in the study eye.

No severe foveal atrophy on OCT.

Able and willing to comply with postoperative positioning and follow-up visits.

Written informed consent provided.

Exclusion Criteria:

A. Etiology-Related / Secondary Macular Holes:

Traumatic macular hole.

High myopia with posterior staphyloma (axial length >28 mm and/or spherical equivalent ≤-8.0 D).

Diabetic tractional retinal detachment (TRD) or significant tractional maculopathy.

Retinal vascular occlusion-related macular hole.

Uveitis-related macular hole.

Advanced age-related macular degeneration (AMD) with foveal atrophy.

B. Prior Interventions:

Any prior pars plana vitrectomy in the study eye.

C. Ocular Conditions That May Affect Outcomes or Safety:

Active or recent ocular infection or inflammation (e.g., uveitis, endophthalmitis, keratitis).

Uncontrolled glaucoma (intraocular pressure >28 mmHg despite treatment).

Media opacity precluding adequate OCT (e.g., dense cataract or corneal opacity).

Geographic atrophy involving the fovea.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
有源比较器:PPV + PVD Induction Without ILM Peel/Flap
Pars plana vitrectomy (PPV) with induction of posterior vitreous detachment (PVD) performed without internal limiting membrane (ILM) peeling and without an ILM flap.
Pars plana vitrectomy (PPV) for full-thickness macular hole repair performed according to the randomized assigned technique (e.g., ERM peel, ILM peeling, ILM flap configurations, or macular edge hydrodissection), as specified in the protocol.
有源比较器:PPV + ERM peel + circular ILM peel (classic)
Pars plana vitrectomy (PPV) with epiretinal membrane (ERM) peeling (if present) followed by standard circular internal limiting membrane (ILM) peeling around the fovea (classic technique).
Pars plana vitrectomy (PPV) for full-thickness macular hole repair performed according to the randomized assigned technique (e.g., ERM peel, ILM peeling, ILM flap configurations, or macular edge hydrodissection), as specified in the protocol.
有源比较器:PPV + 360° Inverted ILM Flap
Pars plana vitrectomy (PPV) with creation of a circumferential (360°) internal limiting membrane (ILM) flap that is inverted to cover the macular hole, according to the study protocol.
Pars plana vitrectomy (PPV) for full-thickness macular hole repair performed according to the randomized assigned technique (e.g., ERM peel, ILM peeling, ILM flap configurations, or macular edge hydrodissection), as specified in the protocol.
有源比较器:PPV + Superior Hinged ILM Flap
Pars plana vitrectomy (PPV) with creation of a superior hinged internal limiting membrane (ILM) flap left attached at the superior edge and inverted to cover the macular hole, according to the study protocol.
Pars plana vitrectomy (PPV) for full-thickness macular hole repair performed according to the randomized assigned technique (e.g., ERM peel, ILM peeling, ILM flap configurations, or macular edge hydrodissection), as specified in the protocol.
有源比较器:PPV + Temporal Hinged ILM Flap
Pars plana vitrectomy (PPV) with creation of a temporal hinged internal limiting membrane (ILM) flap, left attached at the temporal edge, and inverted to cover the macular hole, according to the study protocol.
Pars plana vitrectomy (PPV) for full-thickness macular hole repair performed according to the randomized assigned technique (e.g., ERM peel, ILM peeling, ILM flap configurations, or macular edge hydrodissection), as specified in the protocol.
有源比较器:PPV + Multiflap ILM Flap (Cabbage Leaf/Star)
Pars plana vitrectomy (PPV) with creation of multiple small internal limiting membrane (ILM) flaps (multiflap "cabbage leaf/star" technique) positioned to cover the macular hole, according to the study protocol.
Pars plana vitrectomy (PPV) for full-thickness macular hole repair performed according to the randomized assigned technique (e.g., ERM peel, ILM peeling, ILM flap configurations, or macular edge hydrodissection), as specified in the protocol.
有源比较器:PPV + ILM removal + inverted flap + PRP
Pars plana vitrectomy (PPV) with internal limiting membrane (ILM) removal and an inverted ILM flap technique. Autologous platelet-rich plasma (PRP) is applied to the macular hole area as an adjunct, according to the study protocol.
Pars plana vitrectomy (PPV) for full-thickness macular hole repair performed according to the randomized assigned technique (e.g., ERM peel, ILM peeling, ILM flap configurations, or macular edge hydrodissection), as specified in the protocol.
Autologous platelet-rich plasma (PRP) applied intraoperatively to the macular hole area as an adjunct to surgery, according to the study protocol.
有源比较器:PPV + ILM removal + PRP
Pars plana vitrectomy (PPV) with standard internal limiting membrane (ILM) peeling (no ILM flap technique). Autologous platelet-rich plasma (PRP) is applied to the macular hole area as an adjunct, according to the study protocol.
Pars plana vitrectomy (PPV) for full-thickness macular hole repair performed according to the randomized assigned technique (e.g., ERM peel, ILM peeling, ILM flap configurations, or macular edge hydrodissection), as specified in the protocol.
Autologous platelet-rich plasma (PRP) applied intraoperatively to the macular hole area as an adjunct to surgery, according to the study protocol.
有源比较器:PPV + ILM Peeling + Human Amniotic Membrane (hAM) Graft
Pars plana vitrectomy (PPV) with standard internal limiting membrane (ILM) peeling followed by placement of a human amniotic membrane (hAM) graft for full-thickness macular hole repair, according to the study protocol.
Pars plana vitrectomy (PPV) for full-thickness macular hole repair performed according to the randomized assigned technique (e.g., ERM peel, ILM peeling, ILM flap configurations, or macular edge hydrodissection), as specified in the protocol.
Human amniotic membrane (hAM) graft placed intraoperatively for macular hole repair, according to the study protocol.
有源比较器:PPV + Macular Edge Hydrodissection
Pars plana vitrectomy (PPV) with controlled hydrodissection (hydromobilization) of the macular hole edges using balanced salt solution to gently separate and mobilize the retinal margins before macular hole closure, according to the study protocol.
Pars plana vitrectomy (PPV) for full-thickness macular hole repair performed according to the randomized assigned technique (e.g., ERM peel, ILM peeling, ILM flap configurations, or macular edge hydrodissection), as specified in the protocol.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Macular Hole Closure at 7 days
大体时间:7 day
Proportion of participants with OCT-confirmed anatomical macular hole closure.
7 day
Macular Hole Closure at 1month
大体时间:1 month
Proportion of participants with OCT-confirmed anatomical macular hole closure.
1 month
Macular Hole Closure at 1 Year
大体时间:1 year
Proportion of participants with OCT-confirmed anatomical macular hole closure.
1 year

次要结果测量

结果测量
措施说明
大体时间
BCVA at Day 7
大体时间:7 days
Best-corrected visual acuity (BCVA) measured at Day 7 after surgery and recorded in logMAR units.
7 days
BCVA at 1 Month
大体时间:1 month
Best-corrected visual acuity (BCVA) measured at 1 month after surgery and recorded in logMAR units.
1 month
BCVA at 1 Year
大体时间:1 year
Best-corrected visual acuity (BCVA) measured at 1 year after surgery and recorded in logMAR units.
1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sanzhar Sambet Sambet, MD、Kazakh Eye Research Institute

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月25日

初级完成 (估计的)

2027年5月27日

研究完成 (估计的)

2028年5月27日

研究注册日期

首次提交

2026年5月15日

首先提交符合 QC 标准的

2026年5月19日

首次发布 (实际的)

2026年5月26日

研究记录更新

最后更新发布 (实际的)

2026年6月2日

上次提交的符合 QC 标准的更新

2026年5月29日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

This study does not plan to share individual participant data (IPD) publicly. De-identified aggregated results may be shared in publications and presentations.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅